keyword
MENU ▼
Read by QxMD icon Read
search

Ranibizumab

keyword
https://www.readbyqxmd.com/read/28234806/choroidal-blood-flow-and-thickness-as-predictors-for-response-to-anti-vascular-endothelial-growth-factor-therapy-in-macular-edema-secondary-to-branch-retinal-vein-occlusion
#1
Masahiro Okamoto, Mariko Yamashita, Taiji Sakamoto, Nahoko Ogata
PURPOSE: To determine the choroidal blood flow and subfoveal choroidal thickness (SCT) in eyes with macular edema secondary to branch retinal vein occlusion (BRVO). METHODS: Thirty-two eyes of 32 patients with macular edema secondary to a BRVO were treated with a single intravitreal injection of ranibizumab (IVR) and were followed for 2 months. The central retinal thickness and SCT, and the retinal and choroidal blood flows were evaluated, and they were compared between the recurrent and resolved groups...
February 23, 2017: Retina
https://www.readbyqxmd.com/read/28234781/hormonal-supplementation-triggering-choroidal-neovascularization-in-healthy-young-females
#2
Rosa Dolz-Marco, Nuria Doménech, Teresa Diago, Javier Montero, Sara GarcíaCanet, Enrique Cervera-Taulet, Roberto Gallego-Pinazo, J Fernando Arévalo
PURPOSE: To report three cases of choroidal neovascularization after hormonal treatment for ovarian stimulation during a fertility therapy. METHODS: A comprehensive ophthalmic examination was performed in all cases including best-corrected visual acuity, color fundus examination, fluorescein angiography, and optical coherence tomography. RESULTS: Three females in their thirties developed unilateral acuity vision loss and metamorphopsia. They all were undergoing hormonal supplementation for ovarian stimulation with gonadotropins at the moment of presentation...
February 23, 2017: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/28234353/response-to-comment-on-treatment-patterns-of-ranibizumab-intravitreal-injection-and-dexamethasone-intravitreal-implant-for-retinal-vein-occlusion-in-the-usa
#3
S Nghiem-Buffet, S Baillif, S Regnier, A Skelly, N Yu, A Sodi
No abstract text is available yet for this article.
February 24, 2017: Eye
https://www.readbyqxmd.com/read/28223773/erratum-a-single-arm-investigator-initiated-study-of-the-efficacy-safety-and-tolerability-of-intravitreal-aflibercept-injection-in-subjects-with-exudative-age-related-macular-degeneration-previously-treated-with-ranibizumab-or-bevacizumab-assess-study-12-month
#4
https://www.readbyqxmd.com/read/28221256/evaluation-of-macular-ischemia-in-eyes-with-branch-retinal-vein-occlusion-an-optical-coherence-tomography-angiography-study
#5
Shin Kadomoto, Yuki Muraoka, Sotaro Ooto, Yuko Miwa, Yuto Iida, Kiyoshi Suzuma, Tomoaki Murakami, Rima Ghashut, Akitaka Tsujikawa, Nagahisa Yoshimura
PURPOSE: To quantitatively assess macular morphology and perfusion status using optical coherence tomography, and optical coherence tomography angiography in eyes with branch retinal vein occlusion when macular edema has completely resolved, and to investigate the impact on visual function. METHODS: Thirty consecutive eyes with branch retinal vein occlusion-macular edema that resolved after treatment with intravitreal ranibizumab injections were included. Macular sensitivity was measured by microperimetry; defect length of foveal ellipsoid zone band was measured using optical coherence tomography; foveal avascular zone and parafoveal nonperfusion areas (NPA) were measured by optical coherence tomography angiography...
February 17, 2017: Retina
https://www.readbyqxmd.com/read/28214955/ranibizumab-versus-aflibercept-for-macular-edema-due-to-central-retinal-vein-occlusion-18-month-results-in-real-life-data
#6
Irini Chatziralli, George Theodossiadis, Marilita M Moschos, Panagiotis Mitropoulos, Panagiotis Theodossiadis
PURPOSE: The objective of this study was to compare the anatomical and functional outcomes of ranibizumab versus aflibercept for the treatment of macular edema due to central retinal vein occlusion (CRVO) in routine clinical practice. METHODS: Participants in this observational study included 62 treatment-naïve patients with CRVO who received intravitreal injections of either ranibizumab or aflibercept. The demographic data, best-corrected visual acuity (BCVA) and spectral-domain optical coherence tomography (SD-OCT) characteristics were evaluated at baseline and at months 1, 2, 3, 6, 12 and 18 post-treatment...
February 18, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28203186/real-life-iluvien-fluocinolone-acetonide-case-study-rapid-drying-of-the-macula-and-improved-vision-within-2-years-after-therapy-initiation
#7
Hibba Quhill, Fahd Quhill
IMPORTANCE: A case showing sustained structural and functional responses 2 years after a single treatment with ILUVIEN (0.2 µg/day fluocinolone acetonide, FAc) despite suboptimal responses to ranibizumab. OBSERVATIONS: A 68-year-old female patient with diabetic macular oedema (DME) from type 2 diabetes mellitus was first diagnosed in October 2010 and had a baseline visual acuity (VA) of 46 Early Treatment Diabetic Retinopathy Study (ETDRS) letters in the left eye...
September 2016: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/28203056/safety-of-bilateral-same-day-intravitreal-injections-of-anti-vascular-endothelial-growth-factor-agents
#8
Miguel Ruão, María Andreu-Fenoll, Rosa Dolz-Marco, Roberto Gallego-Pinazo
PURPOSE: The aim was to evaluate the safety of bilateral same-day injections with intravitreal antiangiogenic drugs for macular diseases. METHODS: Cross-sectional retrospective review of unilateral and bilateral same-day antiangiogenic injections was conducted between January 2011 and March 2016 in the Unit of Macula, University and Polytechnic Hospital La Fe (Valencia, Spain). A total of 8,172 injections were administered, among which 6,560 were unilateral and 1,612 were bilateral injections...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28192841/6-year-results-of-cnv-secondary-to-pathological-myopia-treated-with-ranibizumab
#9
L Hefner, H Gerding
Background The current standard treatment of choroidal neovascularisation (CNV) secondary to pathological myopia (PM) is intravitreal injection of VEGF antagonists. We now present our 6-year results after treating patients with CNV secondary to PM with ranibizumab. Patients and Methods We retrospectively analysed 15 treatment-naive eyes of 13 patients (10 women, 3 men, mean age 59.2; standard deviation (SD) 11.1; range 41-78 years) with visual impairment related to CNV secondary to PM, who were treated with at least 1 injection of ranibizumab...
February 13, 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/28188433/the-clinical-effectiveness-of-ranibizumab-treat-and-extend-regimen-in-namd-systematic-review-and-network-meta-analysis
#10
REVIEW
Andriy Danyliv, Julie Glanville, Rachael McCool, Alberto Ferreira, Adrian Skelly, Ruth Pulikottil Jacob
INTRODUCTION: Neovascular age-related macular degeneration (nAMD) is a chronic eye condition that causes severe deterioration of vision and ultimately blindness. Two vascular endothelial growth factor inhibitors are approved for nAMD treatment in Europe: ranibizumab and aflibercept. The European license for ranibizumab was updated with an individualized "treat and extend" (T&E) regimen, which involves more proactive treatment based on changes in best corrected visual acuity (BCVA) and/or anatomical outcomes...
February 10, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28182161/combination-verteporfin-photodynamic-therapy-ranibizumab-dexamethasone-in-choroidal-neovascularization-due-to-age-related-macular-degeneration-results-of-a-phase-ii-randomized-trial
#11
Ron P Gallemore, Josh Wallsh, Henry L Hudson, Allen C Ho, Richard Chace, Joel Pearlman
PURPOSE: To assess whether combination therapy (CT) reduces retreatments when compared to ranibizumab monotherapy (RM), while safely maintaining similar vision outcomes. METHODS: In this 24-month trial, patients with age-related macular degeneration (AMD) were randomized to 1) quarter-fluence or 2) half-fluence triple therapy (verteporfin photodynamic therapy [vPDT] + ranibizumab + dexamethasone), 3) half-fluence double therapy (vPDT + ranibizumab), or 4) RM. The primary outcomes were number of retreatment visits and change from baseline in visual acuity (VA) at 12 months...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28176171/comparison-of-efficacy-of-intravitreal-ranibizumab-between-non-vitrectomized-and-vitrectomized-eyes-with-diabetic-macular-edema
#12
Yen-Yi Chen, Pei-Ying Chen, Fang-Ting Chen, Yun-Ju Chen, Jia-Kang Wang
PURPOSE: To compare the efficacy of intravitreal ranibizumab between non-vitrectomized and vitrectomized eyes with diabetic macular edema (DME). STUDY DESIGN: A retrospective, nonrandomized, and comparative study. METHODS: From May 2013 to March 2016, 148 eyes of 148 patients with treatment-naïve center-involving DME were reviewed in one institution. Forty-six eyes underwent prior vitrectomy at least 3 months ago, and 102 eyes did not receive any vitrectomy...
February 7, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28169069/difficulties-in-the-management-of-retinal-capillary-haemangiomas-associated-with-von-hippel-lindau-disease
#13
M Pastor-Montoro, N Hurtado-Montalbán, J A Martínez-Morales, M P Villegas-Pérez
CLINICAL CASE: A 29-year-old female with bilateral retinal capillary haemangiomas (RCH). A genetic analysis was carried out due to the suspicion of von Hippel-Lindau (VHL) disease, with negative results on 2occasions. There was progression of the RCH in the left eye, leading to a macular epiretinal membrane. The patient was treated with laser, intravitreal ranibizumab, and vitrectomy. Finally, a third genetic test detected a de novo mutation in the VHL gene, and led to the genetic diagnosis...
February 3, 2017: Archivos de la Sociedad Española de Oftalmología
https://www.readbyqxmd.com/read/28161147/factors-associated-with-worsening-proliferative-diabetic-retinopathy-in-eyes-treated-with-panretinal-photocoagulation-or-ranibizumab
#14
Susan B Bressler, Wesley T Beaulieu, Adam R Glassman, Jeffrey G Gross, Lee M Jampol, Michele Melia, Mark A Peters, Michael E Rauser
PURPOSE: To compare rates and identify predictive factors for events that represent worsening of proliferative diabetic retinopathy (PDR) in eyes treated with panretinal photocoagulation (PRP) or ranibizumab. DESIGN: Randomized clinical trial (55 United States sites). PARTICIPANTS: Three hundred ninety-four study eyes from 305 adults with PDR, visual acuity (VA) 20/320 or better, and no history of PRP. INTERVENTION: Panretinal photocoagulation or intravitreous ranibizumab injections (0...
February 1, 2017: Ophthalmology
https://www.readbyqxmd.com/read/28154252/development-of-a-sustainable-release-system-for-a-ranibizumab-biosimilar-using-poly-lactic-co-glycolic-acid-biodegradable-polymer-based-microparticles-as-a-platform
#15
Yusuke Tanetsugu, Tatsuaki Tagami, Takayuki Terukina, Takaya Ogawa, Masato Ohta, Tetsuya Ozeki
Ranibizumab is a humanized monoclonal antibody fragment against vascular endothelial growth factor (VEGF)-A and is widely used to treat age-related macular degeneration (AMD) caused by angiogenesis. Ranibizumab has a short half-life in the eye due to its low molecular weight and susceptibility to proteolysis. Monthly intravitreal injection of a large amount of ranibizumab formulation is a burden for both patients and medical staff. We therefore sought to develop a sustainable release system for treating the eye with ranibizumab using a drug carrier...
2017: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/28152140/functional-and-anatomical-outcomes-in-patients-with-serous-retinal-detachment-in-diabetic-macular-edema-treated-with-ranibizumab
#16
Audrey Giocanti-Aurégan, Linda Hrarat, Lise M Qu, Valérie Sarda, Marouane Boubaya, Vincent Levy, Gilles Chaine, Franck Fajnkuchen
Purpose: To assess the effect of serous retinal detachment (SRD) on functional and anatomical outcomes in ranibizumab-treated patients with diabetic macular edema (DME). Methods: All consecutive ranibizumab-treated patients with SRD were included in this retrospective study. For each patient with SRD, a patient without SRD with the same baseline best-corrected visual acuity (BCVA) was randomly included for adjustment on their baseline BCVA. All patients with SRD were included in group 1 (G1) and those without SRD in G2...
February 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28151839/angiopoietin-like-4-correlates-with-response-to-intravitreal-ranibizumab-injections-in-neovascular-age-related-macular-degeneration
#17
Jong Ho Kim, Jae Pil Shin, In Taek Kim, Dong Ho Park
PURPOSE: To investigate whether the aqueous angiopoietin-like 4 (ANGPTL4) level correlates with clinical features in neovascular age-related macular degeneration (AMD). METHODS: The control and study groups consisted of all consecutive patients who received senile cataract surgery or intravitreal ranibizumab injection for treatment-naïve neovascular AMD, respectively. The AMD group received 3 monthly ranibizumab injections followed by monthly pro re nata for at least 12 months...
February 1, 2017: Retina
https://www.readbyqxmd.com/read/28149783/efficacy-and-safety-of-ranibizumab-for-wet-age-related-macular-degeneration-in-chinese-patients
#18
Hui-Jun Qi, Xiao-Xin Li, Jun-Yan Zhang, Ming-Wei Zhao
AIM: To evaluate the clinical efficacy and safety of ranibizumab for wet age-related macular degeneration (wAMD) in Chinese patients and to determine the mean number of injections administered over one year of follow-up. METHODS: This single centre, retrospective observational case series study included data from 121 patients with wAMD (121 eyes) who were diagnosed by indirect ophthalmoscopy, fluorescence fundus angiography (FFA), indocyanine green angiography, and optical coherence tomography...
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/28149782/six-year-outcomes-in-neovascular-age-related-macular-degeneration-with-ranibizumab
#19
Julie Jacob, Heidi Brié, Anita Leys, Laurent Levecq, Filip Mergaerts, Kris Denhaerynck, Stefaan Vancayzeele, Eline Van Craeyveld, Ivo Abraham, Karen MacDonald
AIM: To evaluate the outcomes of ≥6y ranibizumab therapy in neovascular age-related macular degeneration (AMD). METHODS: HELIX was a retrospective, observational effectiveness study using medical records of patients treated in three clinics in Belgium. Patients had neovascular AMD and were initially treated with intravitreal ranibizumab (0.5 mg) between November 1, 2007 and October 31, 2008, had ≥6y of data available, and were treated on an ongoing, as-needed basis...
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/28145976/two-year-outcomes-of-treat-and-extend-intravitreal-therapy-using-aflibercept-preferentially-for-neovascular-age-related-macular-degeneration
#20
Daniel Barthelmes, Vuong Nguyen, Vincent Daien, Anna Campain, Richard Walton, Robyn Guymer, Nigel Morlet, Alex P Hunyor, Rohan W Essex, Jennifer J Arnold, Mark C Gillies
PURPOSE: To report 24-month outcomes of a treat and extend (T&E) regimen using aflibercept in eyes with neovascular age-related macular degeneration. METHODS: This was a database observational study that included treatment-naive eyes with neovascular age-related macular degeneration tracked by the Fight Retinal Blindness! outcome registry completing 24 months of sole monotherapy with aflibercept treatment under a T&E regimen between November 1, 2012 and January 31, 2014...
January 31, 2017: Retina
keyword
keyword
1767
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"